Original Source: Systemic Lupus Erythematosus Market
Buy Now: Market Research
GlobalData, the industry analysis specialist’s new report, “Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global systemic lupus erythematosus market. The report identifies the key trends shaping and driving the global systemic lupus erythematosus market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global systemic lupus erythematosus sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts
GlobalData estimated the Systemic Lupus Erythematosus (SLE) market to be worth $350 million in 2009 with a projected Compound Annual Growth Rate (CAGR) of 6% and projected market value to exceed $2.5 billion in 2017. Products for systemic lupus erythematosus in developmental pipeline are strong. The pipeline molecules have a distinct advantage over the currently used off-label marketed drugs. These molecules are primarily first-in-class molecules displaying the robustness of the systemic lupus erythematosus pipeline.
GlobalData finds that the launch of pipeline products may have a superior efficacy in overcoming with the currently marketed products. However, several compounds are in development, and it must be hoped that, many will bring significant relief to number of systemic lupus erythematosus patients in reducing the symptoms. With all these market constraints, the only rational outcome for the new launches would be to provide more safety profile and better efficacy, cost advantage to the market in systemic lupus erythematosus market.
Scope
The scope of the report includes:
- Annualized global systemic lupus erythematosus market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.
- Geographies covered in this report include the
- Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include T and B cell modulators, Immunomodulators, Hormonal Agents, phosphodiesterase type 4inhibitor, Anti Alpha INF, Interleukin inhibitors and anti CD antigens.
- Analysis of the current and future market competition in the global systemic lupus erythematosus market. Key market players covered are F. Hoffmann-La Roche Ltd (Genentech) , MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, UCB S.A, Amgen and Biogen Idec.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with systemic lupus erythematosus.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global systemic lupus erythematosus market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global systemic lupus erythematosus market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global systemic lupus erythematosus market landscape? - Identify, understand and capitalize.
Browse complete report: Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017
Table of contents
1.1 List of Tables 5
1.2 List of Figures 5
2 Systemic Lupus Erythematosus Market : Introduction 6
2.1 GlobalData Pipeline Report Guidance 6
3 Systemic Lupus Erythematosus Market : Market Characterization 7
3.1 Overview 7
3.2 Systemic Lupus Erythematosus Market Size 7
3.3 Systemic Lupus Erythematosus Market Forecast and CAGR 8
3.4 Drivers and Barriers for the Systemic Lupus Erythematosus Market 9
3.4.1 Drivers for the Systemic Lupus Erythematosus Market 9
3.4.2 Barriers for the Systemic Lupus Erythematosus Market 9
3.5 Opportunity and Unmet Need 10
3.6 Key Takeaway 11
4 Systemic Lupus Erythematosus Market : Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Major Therapies and Off-Label Marketed Products in the SLE Market 13
4.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13
4.3.2 Corticosteroids 15
4.3.3 Immunosuppressant or Cytotoxic Drugs 15
4.4 Key Takeaway 16
5 Systemic Lupus Erythematosus Market : Pipeline Assessment 17
5.1 Overview 17
5.2 Strategic Pipeline Assessment 17
5.2.1 Technology Trends Analytic Framework 17
5.3 SLE Therapeutics – Promising Drugs under Clinical Development 19
5.4 Molecule Profile for Promising Drugs under Clinical Development 20
5.4.1 Benlysta (belimumab) 20
5.4.2 Atacicept 22
5.4.3 Ocrelizumab (Humanized Anti-CD20 monoclonal antibody) 23
5.4.4 Prestara™ 24
5.4.5 Epratuzumab 25
5.4.6 Lupuzor 25
5.5 Systemic Lupus Erythematosus Therapeutics – Pipeline by Clinical Phases of Development 26
5.5.1 Systemic Lupus Erythematosus Therapeutics – Phase III Clinical Pipeline 26
5.5.2 Systemic Lupus Erythematosus Therapeutics – Phase II Clinical Pipeline 27
5.5.3 Systemic Lupus Erythematosus Therapeutics – Phase I Clinical Pipeline 28
5.5.4 Systemic Lupus Erythematosus Therapeutics – Preclinical Pipeline 29
5.5.5 Systemic Lupus Erythematosus Therapeutics – Discovery Pipeline 29
5.6 Discontinued/Suspended Drugs for Systemic Lupus Erythematosus 29
5.7 Key Takeaway 30
6 Systemic Lupus Erythematosus Market : Implications for Future Market Competition 31
7 Systemic Lupus Erythematosus Market: Future Players 32
7.1 Introduction 32
7.2 Biogen Idec 32
7.2.1 Overview 32
7.2.2 Autoimmune Portfolio 33
7.3 MedImmune 34
7.3.1 Overview 34
7.3.2 Autoimmune Portfolio 34
7.4 F. Hoffmann-La Roche (Genentech) 35
7.4.1 Overview 35
7.4.2 Autoimmune Portfolio 35
7.5 Amgen Inc 36
7.5.1 Overview 36
7.5.2 Autoimmune Portfolio 36
7.6 Bristol-Myers Squibb 37
7.6.1 Overview 37
7.6.2 Autoimmune Portfolio 37
7.7 UCB S.A 38
7.7.1 Overview 38
7.7.2 Autoimmune Portfolio 38
7.8 GlaxoSmithKline plc 40
7.8.1 Overview 40
7.8.2 Autoimmune Portfolio 40
8 Systemic Lupus Erythematosus Market : Appendix 44
8.1 Market Definitions 44
8.2 Scope of Pipeline Research 44
8.3 Abbreviations 44
8.4 Research Methodology 45
8.4.1 Coverage 46
8.4.2 Secondary Research 46
8.4.3 Forecasting 46
8.4.4 Primary Research 49
8.4.5 Expert Panel validation 49
8.5 Contact Us 49
8.6 Disclaimer 49
8.7 Sources 50
Browse all Pharmaceuticals Market
Browse all GlobalData Market
Browse all Latest Report
Related Reports:
About Us:
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.
Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.
We also provide 24/7 online and offline support to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org/
